Read about NervGen and its research in Alzheimer’s in this article in Health Europa
Read about NervGen and our preclinical results in stroke in this article in BioSpace
New Scientist’s Carissa Wong writes about NervGen’s potential in stroke following Cell Reports publication
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Contact
2955 Virtual Way
Suite 480
Vancouver, BC V5M 4X6
Phone: (778) 731-1711
Email: info@nervgen.com